GlaxoSmithKline’s chief executive said a shareholder vote in favour of spinning off its consumer healthcare business vindicated the UK drugmaker’s decision to turn down a ￡50bn takeover offer from Unilever for its joint venture with Pfizer.
In a ballot at the company’s general meeting, 99.8 per cent of investors who voted backed two resolutions needed to enable the demerger of Haleon, paving the way for the largest London listing in a decade.
The spin-off will take place on July 18, with each GSK investor receiving one share in Haleon for each share they own in the parent.
您已閱讀19%（577字），剩余81%（2416字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。